Aiforia vs Mindpeak (2026)
Both are CE marked algorithm vendors with no FDA clearance, both grade A on AI centrality, and both are assistive by design, so the choice is breadth versus depth and where the evidence comes from. If you need broad multi tumor CE coverage or want to build your own models, start with Aiforia. If you want deep, independently validated breast biomarker quantification embedded in a platform you may already run, start with Mindpeak. Aiforia sells clinical suites across five tumor types plus lymph node and offers a model building engine, but its evidence is largely adoption signal and research. Mindpeak concentrates on breast immunohistochemistry, the highest volume workload in European pathology, and is the one vendor in this group whose validation is genuinely independent rather than vendor run.
- Breadth: CE-IVD clinical suites across breast, prostate, lung, colorectal, and gastric cancer plus lymph node metastasis, versus Mindpeak's concentration in breast immunohistochemistry.
- A build your own capability: the Aiforia Create platform lets pathologists develop their own models, which has produced a large body of research use models, with no equivalent from Mindpeak.
- Vendor stability visibility: its Helsinki listing forces financial disclosure that most private competitors in this group do not provide.
- The only genuinely independent evidence in this group: third party studies, including work by Abele and colleagues on Ki-67, ER, and PR and a concordance study at Aga Khan University Hospital, rather than vendor run validation.
- Depth where the volume is: breast immunohistochemistry covering HER2, ER, PR, and Ki-67, with a cell level classification distinguishing tumor from non tumor structures.
- Lower adoption friction: distributed inside PathAI's AISight since 2025, so for laboratories already on that platform adoption is algorithm selection rather than an integration project.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Aiforia and Mindpeak are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Aiforia | Mindpeak |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2013 | 2018 |
| Headquarters | Helsinki, Finland | Hamburg, Germany |
| Website | aiforia.com | mindpeak.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Aiforia its top capability grade on AI Centrality and Security Certifications and Trust Center. Set against Mindpeak, Aiforia grades higher on Model Supply Chain Disclosure, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Mindpeak its top capability grade on AI Centrality. Set against Aiforia, Mindpeak grades higher on EHR and Interoperability Depth and Deployment Model and Data Residency. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Aiforia or Mindpeak?
On the axes where the AI Health Index separates them, Aiforia grades higher on Model Supply Chain Disclosure, HIPAA and BAA Posture and Security Certifications and Trust Center, and Mindpeak grades higher on EHR and Interoperability Depth and Deployment Model and Data Residency. Aiforia leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Aiforia and Mindpeak differ most?
The widest separation the AI Health Index records between Aiforia and Mindpeak is on Security Certifications and Trust Center, where Aiforia grades A and Mindpeak grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Aiforia and Mindpeak grade the same?
The AI Health Index grades Aiforia and Mindpeak the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Aiforia and Mindpeak not disclosed?
At the last review, at least one of Aiforia and Mindpeak published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Both are CE-IVD only with no FDA clearance, so neither is deployable for US clinical diagnosis without a separate path, and both report evidence as concordance and efficiency rather than patient outcome. Neither publishes pricing, a security attestation, or demographic subgroup analysis.
Aiforia's headline efficiency figures, for example up to 40 percent pathologist time saved on lymph node review, are vendor quoted and not independently verified, and its integration depth is asserted through partnerships such as Siemens Healthineers rather than an enumerated connector list.
Mindpeak's clinical coverage is narrower than its full product list suggests, since its prostate and other assays are research use only, and because its algorithms run inside a third party platform, data residency and stewardship follow the host rather than Mindpeak.